NIH Special SCIENCE SERIES (#5): Cancer Vaccine – Unique Tumor-Associated Antigen

NIH Special SCIENCE SERIES (#5): Cancer Vaccine – Unique Tumor-Associated Antigen

This webinar has already taken place. However, you can watch a recording of it by clicking on the screen shot just below.

Originally aired on February 18th, 2016

FREE take-away: To know more about this technology, please download the PDF here.

One Million Solutions in Health™ has established a one-of-a-kind, new partnership with the United States’ National Institutes of Health Office of Technology Transfer (NIH-OTT) and the National Cancer Institute Technology Transfer Center (NCI-TTC) to increase awareness and understanding of NIH technologies by potential partners in the life science and healthcare industries.

This provides you with a front-row seat to hear about new technology and science from various scientists at the NIH.

Soon, this opportunity to learn directly from a number of NIH scientists, will ONLY be made available to members of our Technology Evaluation Consortium™ (TEC). But, for the next few months, this information is being shared beyond our current membership, to provide you and/or your organization with the opportunity to join the consortium.

This is also your opportunity to participate in our exclusive Signature Square™ process, where end-users rate and evaluate the technology, providing feedback directly to the scientist, to help effect and drive the NIH research Road Map for this technology.

CANCER VACCINE — UNIQUE TUMOR-ASSOCIATED ANTIGEN

–  This presentation features an exceptional discovery in the search for unique cancer antigens.
–  NIH scientists have isolated a tumor-associated antigen (TAA) that is widely expressed in various human tumors.
–  THIS SETS THE STAGE FOR A CANCER VACCINE SOLUTION.

A NEW PATENT WILL BE ISSUED ON THIS TECHNOLOGY VERY SOON.

Importantly, this TAA contains a number of immune dominant regions/epitopes that are readily recognized by human T cells. It has been shown that humans can efficiently elicit specific helper and cytolytic T cells capable of killing human tumors.

– This antigen is over-expressed in metastatic cancers
– Human T cells elicit responses to this antigen and kill the tumor’s expression of this antigen
– This has the potential to allow your own body to mount an attack against your own tumor to kill it

The focus is to understand how immune cells control diseases like cancer, and how we can use this knowledge to develop potent therapeutic formulations to combat cancer.

Cancer strategies often don’t cure patients, and patients often relapse. To illicit long-lasting, disease-free survival, current thinking suggests the need to induce immune responses against cancer.

To do this, a number of strategies can be utilized under the auspices of cancer immunotherapy. In considering a cancer vaccine, in order to be effective, it needs to have a unique target, against which immune cells will be responding.

If you are searching for unique targets/antigens for immunotherapy in cancer vaccines, this presentation is for you.

Current member companies in the Signature Square program include organizations like Pfizer, AbbVie, Amgen and Allergan, along with many others. However, on a trial basis, we are allowing new industry participants, and other scientists, clinicians and investors in organizations around the world, to evaluate this technology and take part in this Signature Square evaluation entitled “NIH SPECIAL Science SERIES: CANCER VACCINE – UNIQUE TUMOR-ASSOCIATED ANTIGEN” on Thursday, February 18th at 11 am EST.

 

PANELISTS
	SPEAKER: Dr. Bira Arya Senior Investigator National Institute on Aging – IRP
	MODERATOR: Dawn Van Dam President & CEO One Million Solutions in Health™